CA 15-3 and bone scintigraphy in the follow-up of breast cancer

International Journal of Biological Markers

Volumn 12, Issue 4, 1997, Pages 154-157

  Younsi, N ^a   Montravers, F ^a   Philippe, C ^a   Seddiki, M ^a   Uzan, S ^a   Izrael, V ^a   Talbot, J N ^a  

^a HÔPITAL TENON   (France)

Author keywords

Bone scintigraphy; Breast cancer follow up; CA 15 3; CEA; Strategy of examinations

Indexed keywords

CA 15-3 ANTIGEN; OXIDRONATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BREAST CANCER; CANCER SCINTISCANNING; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY;

EID: 0031411685     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460089701200403     Document Type: Article

References (9)

1. Montravers F, Younsi N, Rousseau C, et al. Comparison of bone scanning and CA 15-3 serum concentration in the follow-up of breast cancer. Anticancer Research 1997; 17: 1683-6.
2. Haubold-Reuter BG, Duewell S, Schilcher BR, Marincek B, Schulthess G. The value of bone scintigraphy, bone marrow scintigraphy and fast spin-echo magnetic resonance imaging in staging of patients with malignant solid tumours: a prospective study. Eur J Nucl Med 1993; 20: 1063-9.
3. Janicek MJ, Shaffer K. Scintigraphic and radiographic patterns of skeletal metastases in breast cancer: value of sequential imaging in predicting outcome. Skeletal Radiol 1993; 24: 497-600.
4. Lee YTN. Bone scanning in patients with early breast carcinoma: Should it be a routine staging procedure? Cancer 1981; 47: 486-95.
5. Sherry MM, Greco FA, Johnson DH, Hainsworth JD. Metastatic breast cancer confined to the skeletal system. Am J Med 1986; 81: 381-6.
6. Safi F, Kohler I, Röttinger E, Beger HG. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. Cancer 1991; 68: 574-82.
7. Martoni A, Ercolino L, Bellanova B, Zanichelli L, Canova N, Panuti F. CA 15.3 and CEA plasma level monitoring in patients with breast cancer. Int J Biol Markers 1988; 3: 154-8.
8. Omar YT, Behbehani AE, Al-Naqeeb N, et al. Carcinoembryonic antigen and breast carcinoma antigen (CA 15.3) in preoperative staging and postoperative monitoring of patients with carcinoma of the breast. Int J Biol Markers 1988; 3: 165-71.
9. Crippa F, Bombardieri E, Seregni E, et al. Single determination of CA 15.3 and bone scintigraphy in the diagnosis of skeletal metastases of breast cancer. J Nucl Biol Med 1992; 36: 52-5.